Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 11/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330764 | 0.85 | HTR2C (0.68) | HTR2CHTR2BHTR6PNMT | |
| SCHEMBL3896981 | 0.74 | SLC2A1 (0.41) | HTR2CHTR2BHTR6SMN1; SMN2TSHR | |
| SCHEMBL3151103 | 0.73 | ALDH1A1 (0.48) | SMN1; SMN2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9914244 | 0.71 | POLB (0.51) | HTR6SMN1; SMN2TSHRALDH1A1POLB | |
| SCHEMBL9914242 | 0.71 | ALDH1A1 (0.45) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16574199 | 0.71 | PTGS2 (0.61) | ALDH1A1 | |
| SCHEMBL10158484 | 0.71 | PNMT (0.56) | HTR2CHTR2BHTR6DRD2DRD3 | |
| SCHEMBL6332067 | 0.71 | NOTUM (0.44) | HTR2CHTR2BSMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL7510471 | 0.70 | CA12 (0.47) | SMN1; SMN2TSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27871204 | 0.70 | CA2 (0.64) | ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | claimed |
| EP-1456178-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | claimed |
| WO-2003062205-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-31 | — | — | WO | claimed |
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1456178-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003062205-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | MPL, HTR2B, PDGFRB | HTR2C 49/4885HTR2B 2/4885HTR6 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.